Companies/Lexaria Bioscience Corp.

Company profile

Lexaria Bioscience Corp.

NASDAQ: LEXX · Healthcare · Biotechnology

Canadian filerHQ Kelowna, BCCIK 0001348362Reports USD

#896 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

43D

FH 37DQ 44GM 68SS 31

v0.1 · 65/100 weight · provisional

↑ Altman-Z, 3-yr revenue growth · ↓ return on equity, return on assets

Methodology →

Revenue TTM

$368.0k

Rev growth YoY (TTM)

-30.0%

Net income (FY)

-$11.9M

Employees

Market cap

$11.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$705.9k$705.9k2025

Net income-$11.9M-$11.9M2025

Operating income-$11.9M-$11.9M2025

Total assets$4.2M$4.2M2025

Liabilities$1.6M$1.6M2025

Equity$3.0M$3.0M2025

Revenue trend

FY2019 – FY2025 · USD

$433.3k

FY19

$222.6k

FY19

$384.5k

FY20

$722.7k

FY22

$255.4k

FY22

$226.2k

FY23

$464.3k

FY24

$705.9k

FY25

Revenue by segment

Filed disclosures · FY2025

By product

IP Licensing99%

B2B1%

By geography

Not disclosed.

The read

Lexaria Bioscience Corp. booked $705.9k in FY2025 revenue, growing 52% year over year — faster than most Healthcare companies we track, at a -1686.0% net margin.

Peers · Healthcare

VYNE Therapeutics Inc.38D Phio Pharmaceuticals Corp.40D Kiora Pharmaceuticals, Inc.52D VolitionRX Ltd38D

Key facts

CEORichard C. Christopher

SectorHealthcare

IndustryBiotechnology

HeadquartersKelowna, BC

ExchangeNASDAQ: LEXX

Employees7

IPO date2021-01-12

Latest filings

10-Q2026-04-13 8-K2026-02-06 8-K2026-01-28 10-Q2026-01-13 8-K2025-12-16 DEF 14A2025-12-10 10-K2025-11-28 8-K2025-09-29

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.